+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NASH Drug Pipeline and Market Overview

  • ID: 4985245
  • Report
  • January 2020
  • Region: Global
  • 18 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • Allergan
  • Galectin
  • Genfit
  • Gilead
  • Immuron
  • Intercept
  • MORE

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate.

In addition, the report provides the following data:

  • Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day Supply
  • NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)

In creating its market forecast, the analyst discusses the indicators that needed to be evaluated to create this estimate, commenting on:

  • NASH Disease Incidence and Prevalence
  • NAFLD Incidence and Prevalence
  • Risk Factor Evaluation
  • Pricing Trends
  • Liver Transplant Statistics and Trends
  • Expected Market Penetration
  • Global Treatment Options and Emerging Therapies
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • Galectin
  • Genfit
  • Gilead
  • Immuron
  • Intercept
  • MORE

Chapter 1: Executive Summary

  • Introduction
  • Market Summary
  • Competitive Summary

Chapter 2: NASH

  • Overview

Chapter 3: Products in Development

  • Introduction
  • Products in Development
    • Table 3-1: Products in Development for the Treatment of NASH 2019

Chapter 4: Market Opportunity

  • Overview
    • Figure 4-1: NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)
  • Market Forecast Indicators
  • NASH Disease Incidence and Prevalence
  • NAFLD Incidence and Prevalence
  • Risk Factor Evaluation
    • Figure 4-2: Obesity and Diabetes Prevalence Rates (% of Population), 2016
  • Pricing Trends
    • Table 4-1: Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day supply
  • Liver Transplant Statistics and Trends
    • Figure 4-3: Liver Transplant Distribution by World Region, 2018 (Europe, Americas, Western Pacific, South-East Asia, Africa, Eastern Mediterranean)
  • Expected Market Penetration
  • Global Treatment Options and Emerging Therapies
  • Competitive Overview
    • Intercept
    • Genfit
    • Allergan
    • Madrigal
    • Immuron
    • Galectin
    • Gilead
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan
  • Galectin
  • Genfit
  • Gilead
  • Immuron
  • Intercept
  • Madrigal
Note: Product cover images may vary from those shown
Adroll
adroll